
Amgen AMGN
$ 346.45
-0.43%
Annual report 2025
added 02-13-2026
Amgen Cash Conversion Cycle 2011-2026 | AMGN
Annual Cash Conversion Cycle Amgen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 217 | 261 | 327 | 246 | 213 | 200 | 249 | 209 | 185 | 211 | 177 | 165 | 296 | 283 | 345 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 345 | 165 | 239 |
Quarterly Cash Conversion Cycle Amgen
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 255 | - | - | - | 240 | - | 228 | 214 | 225 | - | 209 | 218 | 205 | - | 259 | 263 | 233 | - | 208 | 208 | 211 | - | 188 | 183 | 53.5 | - | 49.7 | 50.8 | 50.9 | - | 47.8 | 50.9 | 50.2 | - | 46.2 | 44.9 | 52.9 | - | 51.8 | 52.6 | 56.1 | - | 53.2 | 51.3 | 61 | - | 67 | 66.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 263 | 44.9 | 133 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akebia Therapeutics
AKBA
|
42 | $ 1.35 | -2.17 % | $ 347 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 330.71 | 3.72 % | $ 43.3 B | ||
|
Altimmune
ALT
|
7.85 K | $ 3.47 | 3.89 % | $ 306 M | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Amneal Pharmaceuticals
AMRX
|
117 | $ 12.37 | -0.92 % | $ 3.88 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Anika Therapeutics
ANIK
|
270 | $ 15.0 | 1.32 % | $ 220 M | ||
|
ANI Pharmaceuticals
ANIP
|
235 | $ 76.34 | 2.87 % | $ 1.47 B | ||
|
Aptorum Group Limited
APM
|
-400 | $ 0.92 | -1.11 % | $ 5.02 M | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Aquestive Therapeutics
AQST
|
-172 | $ 4.15 | 0.48 % | $ 444 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.43 | 4.98 % | $ 231 M | ||
|
Ardelyx
ARDX
|
885 | $ 6.08 | 2.27 % | $ 1.47 B | ||
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Arcutis Biotherapeutics
ARQT
|
158 | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
4.66 | $ 11.11 | 2.4 % | $ 788 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 61.57 | 0.88 % | $ 8.24 B | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Assembly Biosciences
ASMB
|
25.1 | $ 30.01 | 3.43 % | $ 336 M | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Atossa Therapeutics
ATOS
|
-2.25 K | $ 5.21 | -2.89 % | $ 44.9 M | ||
|
Atara Biotherapeutics
ATRA
|
4.13 | $ 5.03 | 0.7 % | $ 63.1 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
612 | $ 16.04 | 2.75 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
119 | $ 1.42 | 0.35 % | $ 378 M | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B |